Onkologie. 2025:19(5):294-298 | DOI: 10.36290/xon.2025.053

Current landscape of precision medicine in oncology

Alžběta Hlodáková1, Martin Palkovský1, Peter Priester2, Jindřich Kopecký2
1 Onkologická klinika FN Královské Vinohrady a 3. LF UK, Praha
2 Klinika onkologie a radioterapie LF a FN Hradec Králové

This review article summarizes the current state and trends in the field of precision medicine in oncology. Precision medicine utilizes advanced molecular profiling technologies, particularly genomics, transcriptomics, and proteomics, to individualize cancer treatment based on the biological characteristics of each tumor. The article clarifies the distinction between precision and personalized medicine and presents key molecular tools, such as next-generation sequencing (NGS), liquid biopsy, and molecular tumor boards. Established examples of targeted therapies and immunothe­rapies are discussed, including the use of driver mutations and predictive biomarkers. Special attention is given to current challenges in clinical implementation, such as the need for standardization, accessibility, and interdisciplinary collaboration. Looking forward, the field is expected to expand toward tumor-agnostic approaches and broader integration of multi-omics strategies.

Keywords: precision medicine, molecular profiling, targeted therapy, immunotherapy, genomics, oncology.

Accepted: November 25, 2025; Published: December 15, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hlodáková A, Palkovský M, Priester P, Kopecký J. Current landscape of precision medicine in oncology. Onkologie. 2025;19(5):294-298. doi: 10.36290/xon.2025.053.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 15.12.2026

    References

    1. Schwaederle M, Zhao M, Lee JJ, et al. Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. JAMA Oncol. 2016;2(11):1452-1459. Go to original source... Go to PubMed...
    2. Rosario SR, Long MD, Affronti HC, et al. Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas. Nature Communications. 2018;9(1):5330. Go to original source... Go to PubMed...
    3. Wheler J, Lee JJ, Kurzrock R Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. Cancer Res. 2014;74(24):7181-7184. Go to original source... Go to PubMed...
    4. Rodon J, Soria JC, Berger R, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019;25(5):751-758. Go to original source... Go to PubMed...
    5. Subbiah V, Kurzrock R. The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match. Oncologist. 2019;24(1):1-3. Go to original source... Go to PubMed...
    6. Jennings LJ, Arcila ME, Corless C, et al. Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2017;19(3):341-365. Go to original source... Go to PubMed...
    7. Salami SS, Singhal U, Spratt DE, et al. Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer. JCO Precis Oncol. 2019;3. Go to original source... Go to PubMed...
    8. Abd Elmageed ZY, Yang Y, Thomas R, et al. Neoplastic reprogramming of patient-derived adipose stem cells by prostate can­cer cell-associated exosomes. Stem Cells. 2014;32(4):983-997. Go to original source... Go to PubMed...
    9. Doebley AL, Ko M, Liao H, et al. A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA. Nat Commun. 2022;13(1):7475. Go to original source... Go to PubMed...
    10. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81-94. Go to original source... Go to PubMed...
    11. Snyder MW, Kircher M, Hill AJ, et al. Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. Cell. 2016;164(1-2):57-68. Go to original source... Go to PubMed...
    12. Tsimberidou AM, Fountzilas E, Bleris L, et al. Transcriptomics and solid tumors: The next frontier in precision cancer medicine. Semin Cancer Biol. 2022;84:50-59. Go to original source... Go to PubMed...
    13. Krop I, Ismaila N, Andre F, et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol. 2017;35(24):2838-2847. Go to original source... Go to PubMed...
    14. Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016;375(8):717-729. Go to original source... Go to PubMed...
    15. Kwon YW, Jo HS, Bae S, et al. Application of Proteomics in Cancer: Recent Trends and Approaches for Biomarkers Discovery. Front Med (Lausanne). 2021;8:747333. Go to original source... Go to PubMed...
    16. Wang XY, Xu YM, Lau ATY. Proteogenomics in Cancer: Then and Now. J Proteome Res. 2023;22(10):3103-3122. Go to original source... Go to PubMed...
    17. Yang S, Chen X, Pan Y, et al. Proteins associated with EGFR-TKIs resistance in patients with non-small cell lung cancer revealed by mass spectrometry. Mol Med Rep. 2016;14(5): 4823-4829. Go to original source... Go to PubMed...
    18. Hogervorst MA, van Hattem CC, Sonke GS, et al. Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned. Drug Discov Today. 2024; 29(7):104031. Go to original source... Go to PubMed...
    19. Aldea M, Friboulet L, Apcher S, et al. Precision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision? ESMO Open. 2023;8(5). Go to original source... Go to PubMed...
    20. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021;384(25): 2371-2381. Go to original source... Go to PubMed...
    21. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-1037. Go to original source... Go to PubMed...
    22. Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020;383(14):1328-1339. Go to original source... Go to PubMed...
    23. Wang QA, Chen HW, Wu RC, et al. Update of Diagnosis and Targeted Therapy for ALK+ Inflammation Myofibroblastic Tumor. Current Treatment Options in Oncology. 2023;24(12):1683-1702. Go to original source... Go to PubMed...
    24. Bouffet E, Hansford JR, Garrè ML, et al. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. N Engl J Med. 2023;389(12):1108-1120. Go to original source... Go to PubMed...
    25. O'Malley DM, Krivak TC, Kabil N, et al. PARP Inhibitors in Ovarian Cancer: A Review. Target Oncol. 2023;18(4):471-503. Go to original source... Go to PubMed...
    26. Daly GR, AlRawashdeh MM, McGrath J, et al. PARP Inhibitors in Breast Cancer: a Short Communication. Curr Oncol Rep. 2024;26(2):103-113. Go to original source... Go to PubMed...
    27. Brown TJ, Reiss KA. PARP Inhibitors in Pancreatic Cancer. Cancer J. 2021;27(6):465-475. Go to original source... Go to PubMed...
    28. Agarwal N, Azad AA, Carles J, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402(10398):291-303. Go to original source... Go to PubMed...
    29. Cortes JE, Roboz GJ, Baer MR, et al. Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial. J Hematol Oncol. 2025;18(1):7. Go to original source... Go to PubMed...
    30. Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023;389(7):589-601. Go to original source... Go to PubMed...
    31. Zhu AX, Macarulla T, Javle MM, et al. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol. 2021;7(11): 1669-1677. Go to original source... Go to PubMed...
    32. Lee M, Samstein RM, Valero C, et al. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. Hum Vaccin Immunother. 2020;16(1): 112-115. Go to original source... Go to PubMed...
    33. Yamamoto H, Watanabe Y, Maehata T, et al. Microsatellite instability in cancer: a novel landscape for diagnostic and therapeutic approach. Arch Toxicol. 2020;94(10):3349-3357. Go to original source... Go to PubMed...
    34. Ellebaek E, Khan S, Bastholt L, et al. PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma. European Journal of Cancer. 2024;198. Go to original source... Go to PubMed...
    35. Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016;165(1):35-44. Go to original source... Go to PubMed...
    36. Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016;375(9):819-29. Go to original source... Go to PubMed...
    37. Koyama S, Akbay EA, Li YY, et al. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 2016;76(5):999-1008. Go to original source... Go to PubMed...
    38. Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021;384(9):829-841. Go to original source... Go to PubMed...
    39. Nelson BE, Adashek JJ, Lin SH, et al. The abscopal effect in patients with cancer receiving immunotherapy. Med. 2023;4(4):233-244. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.